Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 57.00
Bid: 56.00
Ask: 58.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.571%)
Open: 57.00
High: 57.00
Low: 57.00
Prev. Close: 57.00
MAV4 Live PriceLast checked at -
Maven Income and Growth VCT 4 is an Investment Trust

To achieve long term capital appreciation and generate income by investing the majority of its funds in a diversified portfolio of shares and securities in smaller, unquoted UK companies and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re Offer for Subscription

22 Sep 2017 18:25

RNS Number : 6312R
Maven Income & Growth VCT 4 PLC
22 September 2017
 

Joint Announcement

 

Offer for Subscription

 

22 September 2017

The board of directors of Maven Income and Growth VCT 3 PLC ("Maven VCT 3") and Maven Income and Growth VCT 4 PLC ("Maven VCT 4") (together the "Companies" and each a "Company") are pleased to announce that they have published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription for new Ordinary Shares of 10p each in the Companies to raise, in aggregate, up to £30 million with over-allotment facilities of up to, in aggregate, a further £10 million (before issue costs) (the "Offers").

 

The Companies have also published a joint circular (the "Circular") seeking the approval of their respective shareholders for matters in connection with the Offers, each Company giving notice of a general meeting to be held on 8 November 2017 (the "General Meeting").

 

The Offers will open on 22 September 2017 and are expected to close no later than 3 April 2018 in relation to the tax year 2017/18 and on 20 April 2017 in relation to the tax year 2018/19 (unless the relevant Offer is fully subscribed by an earlier date or previously extended by the relevant board to no later than 14 September 2018).

 

Each Offer is conditional on the passing of all the resolutions at the relevant General Meeting.

Pursuant to individual offer agreements dated 22 September 2017 relating to each Offer between, among others, each relevant Company and Maven Capital Partners LLP ("Maven"), Maven, as the administrator of the Offer, will receive an offer administration fee of 2.5% of the application amount in relation to each accepted application, with reductions to the fee applying in certain cases (for instance, early applications under the Offers). Maven as the investment manager of each Company is a related party of each Company under the Listing Rules, and the payment of such a fee by the Company to Maven is a transaction to which Listing Rule 11.1.10R applies.

Further, William Nixon has expressed his intention, prior to the close of each of the Offers, to subscribe £50,000 in Maven VCT 3 and £50,000 in Maven VCT 4 under the relevant Offer. As a director of each of the Companies, William Nixon is a related party of the relevant Company under the Listing Rules and consequently each subscription is a transaction to which Listing Rule 11.1.10R applies.

Maven VCT 3 has also agreed with Maven that with effect from 1 December 2017 Maven will also be entitled to a performance incentive fee, for each six month period ending 31 May and 30 November, of an amount equal to 15% of any increase in the total return (before applying any performance incentive fee) as at the end of the relevant six month period to the total return (after accruing for the performance incentive fee payable for that period) compared to the end of the last six month period on which a performance incentive fee was paid. Payments in relation to any performance incentive fee shall not exceed £890,000 in relation to any rolling twelve month period ending on the date of the proposed payment. Maven and Maven VCT 3 have also agreed to vary the terms of a co-investment agreement (which enables employees and officers of Maven to co-invest with Maven VCT 3 in certain new and follow-on investments) with the effect that the 8% total investment limit (which applies to the investments that can be made by such employees and officers) will be reduced to 5% with effect from 1 December 2017. As Maven is a related party of Maven VCT 3 under the Listing Rules, the introduction of a performance incentive fee payable by that Company to Maven, together with the variation of the co-investment arrangements, are transactions to which Listing Rule 11.1.10R applies.

To obtain a copy of the Securities Note, private investors and financial advisers should call Maven Capital Partners LLP on 0141 306 7400. A downloadable version of the Securities Note will also be available from the each of the Company's websites: http://www.mavencp.com/migvct3 and http://www.mavencp.com/migvct4 .

 

Copies of the Prospectus and Circular are available, free of charge, from Maven Capital Partners UK LLP at Kintyre House, 205 West George Street, Glasgow G2 2LW.

 

In accordance with the Listing Rules, the Prospectus and Circular have been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

www.morningstar.co.uk/uk/NSM.

 

Any enquiries in respect of the Offers should be directed to:

Maven Capital Partners UK LLP

Telephone: 0141 306 7400E-mail: enquiries@mavencp.com

Maven Capital Partners UK LLPSecretary

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRPGUWPBUPMGMP
Date   Source Headline
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:48 pmRNSIssue of Equity
27th Mar 202410:39 amRNSIssue of Equity
25th Mar 202410:14 amRNSStatement re Offer for Subscription
19th Mar 20245:03 pmRNSTransaction in Own Shares
20th Feb 20242:48 pmRNSDividend Declaration
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:10 amRNSIssue of Equity
17th Jan 202410:03 amRNSDirector/PDMR Shareholding
17th Jan 202410:02 amRNSDirector/PDMR Shareholding
17th Jan 20249:58 amRNSIssue of Equity
15th Jan 20244:28 pmRNSUnaudited Net Value Asset
15th Nov 20235:06 pmRNSTransaction in Own Shares
9th Nov 20233:53 pmRNSNet Asset Value(s)
9th Nov 20233:49 pmRNSResult of General Meeting
13th Oct 20234:56 pmRNSPublication of a Prospectus
13th Oct 202310:17 amRNSDirector/PDMR Shareholding
13th Oct 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
6th Oct 20232:39 pmRNSStatement re Dividend Investment Scheme
8th Sep 20235:01 pmRNSTransaction in Own Shares-Corrective announcement
7th Sep 20233:35 pmRNSTransaction in Own Shares
30th Aug 20232:02 pmRNSHalf-year Report
17th Aug 20233:26 pmRNSStatement re NAV and Interim Dividend
12th Jul 20234:09 pmRNSHolding(s) in Company
10th Jul 20235:06 pmRNSHolding(s) in Company
2nd Jun 202310:05 amRNSDirector/PDMR Shareholding
2nd Jun 20239:43 amRNSIssue of Equity
24th May 20235:10 pmRNSTransaction in Own Shares
23rd May 202310:18 amRNSDirector/PDMR Shareholding
23rd May 202310:17 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20233:38 pmRNSNet Asset Value(s) - Dividend Investment Scheme
11th May 20233:01 pmRNSResult of AGM
11th May 20232:20 pmRNSNet Asset Value(s)
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
13th Apr 20237:00 amRNSAnnual Financial Report
5th Apr 202312:36 pmRNSDirector/PDMR Shareholding
5th Apr 202312:30 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
21st Mar 20234:08 pmRNSTransaction in Own Shares
3rd Mar 20239:56 amRNSIssue of Equity
21st Feb 20234:11 pmRNSUnaudited NAV and Proposed Final Dividend
21st Feb 20233:10 pmRNSUnaudited Net Asset Value, Proposed Final Dividend
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202310:24 amRNSDirector/PDMR Shareholding
8th Feb 202310:17 amRNSDirector/PDMR Shareholding
8th Feb 20239:44 amRNSIssue of Equity
3rd Feb 20233:12 pmRNSProvisional Net Asset Value
23rd Nov 20224:53 pmRNSTransaction in Own Shares
10th Nov 20223:33 pmRNSNet Asset Value(s)
9th Nov 20223:02 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.